Publications by authors named "L Michael"
Draft genome sequences of sp. MMG031 and sp. MMG032 isolated from the dinoflagellate .
Microbiol Resour Announc
December 2024
Here, we report the draft genome sequences of sp. MMG031 and sp. MMG032, isolated from coral-associated dinoflagellate , assembled and analyzed by undergraduate students participating in a Marine Microbial Genomics (MMG) course.
View Article and Find Full Text PDFArticle Synopsis
- * Current tests for measuring Lp(a) often assess total apo(a), which may not accurately reflect Lp(a) levels or the effects of new treatments.
- * A new immunoassay developed for measuring Lp(a) particles showed better accuracy, indicating that muvalaplin's Lp(a)-lowering effects were previously underestimated by commercial tests, while lepodisiran's effects were consistent across both methods.
Article Synopsis
- A recent study showed that muvalaplin effectively inhibits the formation of lipoprotein(a), reducing its levels significantly, with reductions up to 85.8% observed in higher dosages over a 12-week period for those at high cardiovascular risk.
- * The phase 2 trial involved 233 participants with elevated lipoprotein(a) and conditions like atherosclerosis and diabetes, testing different dosages of muvalaplin against a placebo.
- * Results indicated substantial decreases in lipoprotein(a) concentrations and generally demonstrated that muvalaplin is well tolerated, but the long-term effects on high-risk populations require further investigation.
Introduction As part of the Milestones Initiative of the Accreditation Council for Graduate Medical Education (ACGME), residents in neurosurgery are expected to participate in either clinical research or basic science research. Therefore, each neurosurgical training program must offer the support and opportunity to achieve this goal. In 2012, a structured effort to promote a resident culture of research was introduced into the authors' neurosurgery residency training curriculum.
View Article and Find Full Text PDFPurpose Of Review: To review the development of oral agents to lower Lp(a) levels as an approach to reducing cardiovascular risk, with a focus on recent advances in the field.
Recent Findings: Extensive evidence implicates Lp(a) in the causal pathway of atherosclerotic cardiovascular disease and calcific aortic stenosis. There are currently no therapies approved for lowering of Lp(a).